The AIM™ aAPC are synthetic nanoparticles, designed to convey the benefits of cellular therapy with pharmaceutical precision. These nanoparticles are highly modular and can be constructed to achieve precise therapeutic goals and subsequently loaded with a range of specific disease-relevant antigens. The nanoparticles are manufactured with high reproducibility and used to generate an adoptive therapy or as an injectable immunotherapy.
The AIM™ proprietary multi-antigen specific approach is used to up-regulate or down-regulate targeted immune cell function and offers an ideal platform for developing personalized treatments where speed of development is critical and where combinations with other immune modulating or standard of care therapies are needed.
Rapid Loading or Validation of Epitopes
The aAPC can be rapidly loaded with any set of antigen epitopes and quickly evaluated for specific tumors or infectious diseases of interest. Any HLA restricted epitope can be loaded on the aAPC and used to make an AIM™ nanoparticle cocktail.
The AIM™ enrichment and expansion system can be used to validate predicted neo-antigens or epitopes which can be subsequently loaded onto aAPC, creating a AIM™ nanoparticle.
Epitopes from the following antigens have been tested in pre/non-clinical models
Expanding Eligible Populations
The AIM™ nanoparticle can be modified to expand eligible populations by changing Signal 1 (HLA) in a templated Lego-like approach. The POC AIM™ nanoparticle is constructed with HLA-A2, with additional options including HLA-A1, HLA-A11, HLA-A24, HLA-B7 which can be quickly developed. Any combination of modifications to the AIM™ nanoparticle above can be configured in our Lego-like templated approach. This unique feature of the AIM Platform enables fast early proof of concept using the research format and streamlining product development and evolution.
Modifying “Go” or “Kill” Signals
The AIM™ nanoparticle can be modified by changing Signal 2, providing the “Go” or “Kill” signal depending on desired mechanism, using our Lego-like templated approach. A “Go” signal can be used for rapid positive selection to engage and activate target cells, while the “Kill” signal can be used to energize or kill target cells. The POC AIM™ nanoparticle is constructed with anti-CD28 which can be replaced other signals such as anti-41BB or anti-FAS depending on the precise action desired.
Targeting Immune Cell Types
The AIM™ Platform can be used to target other immune cells of choice across MHC Class 1, MHC Class II or CD1 molecules.
Any combination of modifications to the AIM™ nanoparticle above can be configured in our Lego-like templated approach. This unique feature of the AIM™ Platform enables fast early proof of concept using the research format and streamlining product development and evolution.